• May 20, 2024

Olon USA, a seasoned participant at the BIO International Convention, brings a wealth of experience and innovation to this prestigious event. With a rich history of engagement with the biotechnology and pharmaceutical sectors, Olon USA continues to be a trailblazer in driving advancements that benefit both its clients and the industry at large.

At this year’s BIO International Convention, Olon USA is poised to unveil exciting developments and initiatives that showcase its commitment to excellence. From new acquisitions to cutting-edge facilities, Olon USA is at the forefront of high-potency drug development, targeting therapies for critical medical needs such as cancer treatment.

A Focus on High-Potency Manufacturing

The Olon USA team at BIO will include seasoned professionals representing various sectors, including generics, biotechnology, and small molecule pharma development. This diverse expertise ensures that attendees can engage with experts who understand their unique needs and can offer tailored solutions.

One of the highlights of Olon USA’s presence at BIO will be its new high potency suite, located in Ohio. This state-of-the-art facility is designed to meet the growing demand for high-potency compounds, particularly in the anti-cancer market. With capabilities for rapid development and production, Olon USA is poised to make a significant impact in accelerating drug delivery to patients in need.

Driving Innovation in Cancer Treatment

Our high potency suite isn’t just about meeting current demands; it’s about pioneering advancements in cancer treatment. With some of the largest capacities for high-potency manufacturing at the commercial level, Olon S.p.A in Italy sets the stage for groundbreaking developments. However, having this capability locally in the United States opens up a world of possibilities for U.S. companies, particularly in the realm of high-potency compounds crucial for cancer therapy.

The landscape of cancer treatment is evolving, with a significant focus on highly potent compounds. In fact, 60% of new compounds in development for cancer treatment are classified as highly potent. This underscores the critical need for facilities like our high potency suite, which not only meet but also drive the demand for rapid drug development and delivery to patients.

The focus is on Olon USA’s ability to provide early-stage development support, including material production for investigator studies, early cancer treatment trials, and toxicity trials. This extends to projects already underway with CROs, emphasizing Olon USA’s flexibility and expertise in addressing challenges, including geopolitical considerations, to support seamless project progression.

As we look ahead to the end of the year and the beginning of Q1, the demand for high-potency manufacturing is set to skyrocket. Don’t wait until it’s too late. Reach out to us now to discuss how we can support your projects and leverage our high potency suite to drive innovation and accelerate success in cancer treatment.

Seize the Opportunity at BIO and Connect with Olon USA

As the BIO International Convention approaches, Olon USA invites attendees to connect and explore potential collaborations. Whether you are a startup looking for development support, a mid-sized pharma company seeking innovative solutions, or a researcher in need of high-potency manufacturing capabilities, Olon USA is your ideal partner. Our team is eager to engage in meaningful conversations and contribute our expertise to drive mutual success.

Don’t miss the chance to meet the Olon USA team at the BIO International Convention in San Diego. Reach out to schedule a meeting to learn more about how Olon USA can contribute to your project’s success. Let’s innovate together and shape the future of healthcare. We look forward to meeting you at BIO!